Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jaguar HealthJAGX -2.62%21 EBIT per Share is $36.65 as of Mar. 2026. GuruFocus rates JAGX with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 1,173 Biotechnology companies, Jaguar Health ranks worse than 85251.41% on this metric.
Jaguar Health's EBIT per Share for the
three
months ended in Mar. 2026 was $628.13.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $36.65.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Jaguar Health's EBIT per Share or its related term are showing as below:
JAGX's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.5 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Jaguar Health's EBIT for the
three
months ended in Mar. 2026 was $9.42 Mil.
Jaguar Health (NAS:JAGX) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Jaguar Health EBIT per Share Related Terms
Jaguar Health EBIT per Share Historical Data
* Premium members only.
The historical data trend for Jaguar Health's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $36.65
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jaguar Health (JAGX) has a EBIT per Share of $36.65 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Jaguar Health and its competitors. According to the industry distribution chart, Jaguar Health ranks #999999 out of 1173 companies in the Biotechnology industry.
Is Jaguar Health's EBIT per Share too high?
Jaguar Health's current EBIT per Share is $36.65. The Biotechnology industry median EBIT per Share is 15.50. Jaguar Health's value of $36.65 is 136.5% above this industry median. Based on the distribution chart, Jaguar Health ranks #999999 out of 1173 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Jaguar Health has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Jaguar Health's EBIT per Share compare to MBRX and BCDA?
According to the Biotechnology industry distribution chart, Jaguar Health ranks #999999 out of 1173 companies for EBIT per Share. This places Jaguar Health in the lower half of its industry. The industry median EBIT per Share is 15.50. Jaguar Health's value of $36.65 is 136.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jaguar Health's current EBIT per Share of $36.65 is 136.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Jaguar Health and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jaguar Health's current EBIT per Share is $36.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jaguar Health stock overvalued right now?
Jaguar Health (JAGX) has a current EBIT per Share of $36.65. The current EBIT per Share is $36.65 and 136.5% above the Biotechnology industry median of 15.50. Jaguar Health's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Jaguar Health (JAGX), the current EBIT per Share is $36.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
21GF Score
Get the complete analysis for JAGX
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JAGX has been successfully added to your 
